ACROBiosystems Bio-Expo Live February 2026: Quality, Data, And Analytical Solutions

Ensuring patient safety in biologic manufacturing starts long before a drug reaches the clinic. In this session, ACROBiosystems explores how safety-related critical quality attributes like endotoxin, mycoplasma, and sterility are measured, monitored, and maintained throughout the production process.

Discover how ACROBiosystems' SAFENSURE™ assay kits deliver faster turnaround times, higher sensitivity, and end-to-end PCR-based solutions aligned with major pharmacopeias and international biopharmaceutical regulations — without sacrificing accuracy or compliance.

Whether you're optimizing in-process monitoring or preparing for product release, this session has actionable insights for your QC workflow.

About ACROBiosystems

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed to be the cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. ACROBiosystems’ main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.